# Replimune’s twice-rejected melanoma drug prevails in FDA adcomm

> **Open Intelligence Dossier** · First detected: 2026-07-31 16:07 UTC · Category: Business

## Executive Summary
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Replimune’s twice-rejected melanoma drug prevails in FDA adcomm" is generating significant coverage in the Business category, with 2 articles from 2 distinct sources tracked by PULSE so far.


Outlets currently covering the story include WSJ and FirstWord Pharma. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| WSJ | Opinion - Replimune’s Melanoma Therapy Gets a Thumbs Up | [Source Link](https://news.google.com/rss/articles/CBMikwFBVV95cUxNeUM5bHBRZkMxT2xqUXhYUEtxSHk3V2ZvYmhUYWE1ci1KN1JTenBqUG9KWHBzS0VlWTh5UndLQ19peXNoNEdDdlJkUGU2VW5ZSDNkMTQxX25TbVBXclhNSXJaUnp5NFk1aHpKZjhLczhLUnpIUHUyVjM2c2NpQjhOSTNIdnhwWHUyeVpjTWlJb29WTWc?oc=5) |
| FirstWord Pharma | Replimune's oncolytic immunotherapy clears FDA panel despite trial flaws | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTFA0R0k3X08xQnFhdGpJTWxyR1JKdm1qbnRSTDNYOHAyekQ0M2hkaEViZG1DelE5RFZuNW9hN1Q0VmgyVm9adFVOTkZBaElqbDZlY3Rr?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-07-31/replimune-s-twice-rejected-melanoma-drug-prevails-in-fda-adcomm*